Literature DB >> 7905618

Homozygous deletion at chromosome 2q33 in human small-cell lung carcinoma identified by arbitrarily primed PCR genomic fingerprinting.

T Kohno1, K Morishita, H Takano, D N Shapiro, J Yokota.   

Abstract

We have searched for novel genetic alterations in human cancer cell lines by using the arbitrarily primed polymerase chain reaction (AP-PCR), which is a PCR-based genomic fingerprinting. A homozygous deletion was detected in a small-cell lung carcinoma (SCLC) cell line, NCI-H82. Since homozygous deletion is a critical genetic alteration for the inactivation of tumor suppressor gene, we defined the locus of homozygous deletion. Fluorescence in situ hybridization analysis revealed that the deletion was localized at chromosome 2q33. Allelic loss on chromosome 2q was detected in 29.4% (5/17) of SCLC and 37.5% (12/32) one non-SCLC by restriction fragment length polymorphism analysis. Considerably high incidence of allelic loss on chromosome 2q was also detected in colorectal carcinoma and neuroblastoma. These results suggest the presence of a novel tumor suppressor gene at 2q33, which is involved in the development of several human cancers. The size of the homozygous deletion in the NCI-H82 cell line was more than 20 kilobase pairs. Seven loci mapped to 2q32-qter were all retained in this cell line, suggesting the presence of submicroscopic interstitial deletion in this cell line. Homozygous deletion detected in this study should be an invaluable tool for positional cloning of the target tumor suppressor gene at 2q33.

Entities:  

Mesh:

Year:  1994        PMID: 7905618

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  Is caspase-8 a neuroendocrine lung tumor suppressor?

Authors:  Suparna Mazumder; Alexandru Almasan
Journal:  Cancer Biol Ther       Date:  2002 Jan-Feb       Impact factor: 4.742

2.  The cysteine-rich frizzled domain of Frzb-1 is required and sufficient for modulation of Wnt signaling.

Authors:  K Lin; S Wang; M A Julius; J Kitajewski; M Moos; F P Luyten
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

3.  Allelic loss on chromosome 5q34 is associated with poor prognosis in hepatocellular carcinoma.

Authors:  P Saelee; S Wongkham; V Bhudhisawasdi; B Sripa; S Chariyalertsak; S Petmitr
Journal:  J Cancer Res Clin Oncol       Date:  2008-04-02       Impact factor: 4.553

4.  DNA rehybridization during PCR: the 'Cot effect' and its consequences.

Authors:  F Mathieu-Daudé; J Welsh; T Vogt; M McClelland
Journal:  Nucleic Acids Res       Date:  1996-06-01       Impact factor: 16.971

5.  Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridisation.

Authors:  H Tönnies; M R Toliat; C Ramel; U F Pape; H Neitzel; W Berger; B Wiedenmann
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

6.  Genomic homogeneity in fibrolamellar carcinomas.

Authors:  Y Sirivatanauksorn; V Sirivatanauksorn; N R Lemoine; R C Williamson; B R Davidson
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

7.  Nab1, a corepressor of NGFI-A (Egr-1), contains an active transcriptional repression domain.

Authors:  A H Swirnoff; E D Apel; J Svaren; B R Sevetson; D B Zimonjic; N C Popescu; J Milbrandt
Journal:  Mol Cell Biol       Date:  1998-01       Impact factor: 4.272

Review 8.  DNA fingerprinting techniques for the analysis of genetic and epigenetic alterations in colorectal cancer.

Authors:  Johanna K Samuelsson; Sergio Alonso; Fumiichiro Yamamoto; Manuel Perucho
Journal:  Mutat Res       Date:  2010-09-17       Impact factor: 2.433

9.  Frzb-1 is a secreted antagonist of Wnt signaling expressed in the Spemann organizer.

Authors:  L Leyns; T Bouwmeester; S H Kim; S Piccolo; E M De Robertis
Journal:  Cell       Date:  1997-03-21       Impact factor: 41.582

Review 10.  Targeting caspases in cancer therapeutics.

Authors:  Patrick Hensley; Murli Mishra; Natasha Kyprianou
Journal:  Biol Chem       Date:  2013-07       Impact factor: 3.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.